Abstract Details

Title The Effects of Ethanol on the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ezogabine (Retigabine)

Topic Epilepsy

Presentation(s) (-)

Poster/Presentation
Number 209

Objective

Background

Design/Methods

Results

Conclusions

Authors/Disclosures
Christopher Crean (Xyzagen)	Mr. Crean has received personal compensation for serving as an employee of Xyzagen. Mr. Crean has stock in Xyzagen. Mr. Crean has received intellectual property interests from a discovery or technology relating to health care.
Caitlin Loomis, MD	No disclosure on file
	No disclosure on file
Daniel Sanak	No disclosure on file
Kevan E. VanLandingham, MD, PhD, FAAN (US Food and Drug Administration)	Dr. VanLandingham has received personal compensation for serving as an employee of Greenwich Biosciences. Dr. VanLandingham has received stock or an ownership interest from Greenwich Biosciences.

��ɫ��